This is Theresa Agnew, CEO of BioGaia USA. I want to provide an overview of our results for Q3. First off, our sales were 304 million SEK, which was a decline of 4%, mainly due to weaker sales in EMEA as well as some order variability where we had higher orders in Q2 in certain markets. Sales in Europe, Middle East, Africa decreased by 27%, and in Asia Pacific, sales increased by 24%. And in the Americas we had an increase of 5%. There was good growth in Asia Pacific and also solid growth in the Americas.
Our EBIT was 41 million SEK, which was a decline of 65%. This was primarily due to an impairment loss we had, which I will discuss. Our EBIT margin, because of that, was 14% without the impairment loss. If you look at the adjusted EBIT margin, it was 31% and the adjusted EBIT was 93 million, or a decline of 22%. So there were items that affected the comparability in the quarter. It was primarily an impairment loss attributed to our MetaboGen acquisition. And that impairment loss was 51.2 million SEK. I will talk a little about the clinical study that we conducted with prediabetes patients. So in terms of our launches, we had a number of launches: Pharax drops in Switzerland, Nescare B. Lactis in Brazil, and BioGaia Protectis drops with vitamin D in Mexico. BioGaia Prodentis lozenges were launched in a number of markets in Latin America, as well as BioGaia Protectis tablets with vitamin D in Peru, in addition to other key events. We announced in July our exclusive distribution agreement with Recordati in Italy.
As you may know from previous discussions, Recordati was a sub-distributor and is now our exclusive distributor in Italy. On October 17th, we also announced preliminary results indicating that we would not meet market expectations. We had the impairment loss for the MetaboGen acquisition of 51.2 million SEK. This was due to a clinical study that had been ongoing for a number of years, where the primary endpoint for a potential product was not met. This product was focused on metabolic syndrome. So it was a clinical study with about 108 patients looking at glucose values over a 12-week period for people with prediabetes to see if glucose levels would decline with the probiotic versus the placebo. And unfortunately, we did not see the primary endpoint of reduction in glucose. We did have a secondary endpoint where we saw improvements in triglycerides, but our primary endpoints were not met. In terms of sales, as I said, we had an overall 4% decline for the quarter. Our pediatric sales decreased by 12%, mainly due to Protectis drops. And this was mainly in EMEA and the Americas. It was more about Brazil with the order phasing because we had a very high Q2 and then a lower Q3, and sales decreased in Turkey and Spain. Spain was another example where we had higher orders in Q2 and lower orders in Q3. Um, and the adult sales portfolio increased by 29%, mainly due to Prodentis and Protectis tablets. Our sales increased both in the US and in Korea with the Protectis tablets. Increased mainly in Indonesia and Hong Kong. And as you can see from a year-to-date standpoint, our pediatrics business is growing by 4%, and our adult business is growing by 16%. So overall growth of 6% and our pediatric business remains at around 78% of our overall sales. In terms of the regions I mentioned, the EMEA sales decreased by 27%. That was mainly due to Turkey, Spain, and Poland.
In Asia Pacific, we had a healthy increase of 24%, mainly in Indonesia, China, and Australia. Australia is now one of our direct businesses, having transitioned to direct management in Q3. We have a promising start in both Australia and New Zealand. Our China business is performing very well, with increased orders in Q2 and continued higher orders in Q3. So, very strong growth in China. In the Americas, our sales increased by 5%, mainly driven by the US, Canada, and Guatemala. And I'm proud to say in the US and Canada, our business is growing very healthy, ahead of the market. So, as you see here then on the chart. Year to date, EMEA is declining 2%. Asia-Pacific is growing 25%, and the Americas are growing 4%. And it's good to see that our growth in the US is strong, even though we're still lapping the Gerber sales from last year, where they stopped selling our probiotic drops. And now I'll turn it over to Alex to go through the financials in more detail.